{"entity":{"id":"agendia","kind":"company","name":"Agendia","aka":[],"tldr":"Dutch maker of MammaPrint, the 70-gene breast cancer test validated in the MINDACT trial.","summary":"Spun out of the Netherlands Cancer Institute, Agendia developed MammaPrint (FDA-cleared 2007, the first cleared multigene prognostic test) and the BluePrint molecular subtyping assay, and sponsored MINDACT with the EORTC. It also runs the FLEX registry collecting whole-transcriptome data on MammaPrint patients.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://agendia.com"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":["diagnostics"],"technologies":["rna-seq"],"targets":[],"drugs":["mammaprint"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["mindact"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Amsterdam / Irvine, CA","country":"NL","companyType":"diagnostics","website":"https://agendia.com","founded":2003,"investors":[],"funding":[]},"route":"/companies/agendia/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"drug":[{"id":"mammaprint","kind":"drug","name":"MammaPrint (70-gene signature)","route":"/drugs/mammaprint/"}],"trial":[{"id":"mindact","kind":"trial","name":"MINDACT","route":"/trials/mindact/"}]}}